Reported 0 shares, down 120,200 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 633000 |
| 2022-03-31 | 395000 |
| 2022-06-30 | 435000 |
| 2022-09-30 | 1329000 |
| 2022-12-31 | 2530183 |
| 2023-03-31 | 12337387 |
| 2023-06-30 | 12662996 |
| 2023-09-30 | 9960447 |
| 2023-12-31 | 2839124 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -120,200 (-100.0%) | 0 | $0 | 2024-05-15 | |
| Q4 2023 | Reduced | 120,200 | -547,838 (-82.0%) | < 0.01% | $2,839,124 | 2024-02-14 | |
| Q3 2023 | Reduced | 668,038 | -488,400 (-42.2%) | 0.03% | $9,960,447 | 2023-11-14 | |
| Q2 2023 | Reduced | 1,156,438 | -258,400 (-18.3%) | 0.03% | $12,662,996 | 2023-08-14 | |
| Q1 2023 | Added | 1,414,838 | +1,011,300 (250.6%) | 0.03% | $12,337,387 | 2023-05-15 | |
| Q4 2022 | Added | 403,538 | +23,700 (6.2%) | < 0.01% | $2,530,183 | 2023-02-14 | |
| Q3 2022 | Added | 379,838 | +232,300 (157.5%) | < 0.01% | $1,329,000 | 2022-11-14 | |
| Q2 2022 | Added | 147,538 | +20,500 (16.1%) | < 0.01% | $435,000 | 2022-08-15 | |
| Q1 2022 | Reduced | 127,038 | -60,100 (-32.1%) | < 0.01% | $395,000 | 2022-05-16 | |
| Q4 2021 | Reduced | 187,138 | -196,600 (-51.2%) | < 0.01% | $633,000 | 2022-02-14 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
200 managers reported CYMABAY THERAPEUTICS INC for Q1 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| IFP Advisors Inc | Unchanged | 650 | 0 | < 0.01% | $21,077 | 19 qtrs |
| VICTORY CAPITAL MANAGEMENT INC | Reduced | 0 | -689,603 | 0 | $0 | 5 qtrs |
| Hennion & Walsh Asset Management Inc | Reduced | 0 | -78,311 | 0 | $0 | 4 qtrs |
| Metropolitan Life Insurance Co NY | Reduced | 0 | -6,447 | 0 | $0 | 4 qtrs |
| Novo Holdings A S | Reduced | 0 | -900,000 | 0 | $0 | 4 qtrs |
| J Goldman & Co LP | Reduced | 0 | -165,937 | 0 | $0 | 3 qtrs |
| Harvest Fund Management Co Ltd | Reduced | 0 | -1,076 | 0 | $0 | 2 qtrs |
| SUSQUEHANNA INTERNATIONAL GROUP LLP | Reduced | 0 | -68,457 | 0 | $0 | 20 qtrs |
| AMERIPRISE FINANCIAL INC | Reduced | 0 | -25,711 | 0 | $0 | 2 qtrs |
| Verition Fund Management LLC | Reduced | 0 | -10,170 | 0 | $0 | 8 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2024
- Filed
- May 15, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.